Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $21.1 million.

  • Myriad Genetics' Cash from Operations rose 291428.57% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 9685.71%. This contributed to the annual value of -$8.7 million for FY2024, which is 9215.51% up from last year.
  • Latest data reveals that Myriad Genetics reported Cash from Operations of $21.1 million as of Q3 2025, which was up 291428.57% from -$13.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Cash from Operations ranged from a high of $71.8 million in Q1 2021 and a low of -$54.7 million during Q4 2023
  • Over the past 5 years, Myriad Genetics' median Cash from Operations value was -$9.5 million (recorded in 2021), while the average stood at -$11.4 million.
  • As far as peak fluctuations go, Myriad Genetics' Cash from Operations tumbled by 102954.55% in 2022, and later skyrocketed by 291428.57% in 2025.
  • Over the past 5 years, Myriad Genetics' Cash from Operations (Quarter) stood at -$9.5 million in 2021, then increased by 23.16% to -$7.3 million in 2022, then plummeted by 649.32% to -$54.7 million in 2023, then soared by 112.07% to $6.6 million in 2024, then soared by 219.7% to $21.1 million in 2025.
  • Its Cash from Operations was $21.1 million in Q3 2025, compared to -$13.6 million in Q2 2025 and -$16.3 million in Q1 2025.